Cellceutix Aquires New Compound for Autism |
Cellceutix has acquired the rights to the compound KM 391, which it intends to pursue as a treatment for autism. KM 391 is a small molecule that was developed in India and will now be synthesized in the United States for continued testing. Preliminary testing of KM 391 in mice revealed that the test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects in the long-term administration of KM 391 in mice. The equalization of serotonin uptake is considered by many researchers as an important development in the treatment of autism spectrum disorders. Autism is a behavior disorder, characterized by an impairment in social communication, social interaction, and social imagination. Those with autism often have a restricted range of interests and display repetitive behaviors and mannerisms, along with altered reactions to the everyday environment. Autism may affect as many as 14-39 babies per 10,000 births. About Autism Spectrum Disorders:
· 1 percent of the population of children in the U.S. ages 3-17 have an autism spectrum disorder. Prevalence is estimated at 1 in 110 births.
National Institute of Child Health and Human Development (NICHD) Autism Society of America - http://www.autism-society.org
Autism Speaks, Inc. - http://www.autismspeaks.org |